Biotechnology company Judo Bio recently launched with $100 million in series A financing led by Atlas Venture, TCG, and Droia Ventures. The company is focused on delivering precision genetic medicines to the kidney to treat systemic and renal diseases. Rajiv Patni, MD, will serve as its chief executive officer and board director.
Judo Bio has uncovered a novel approach to create oligonucleotide medicines targeted to the kidney, a notoriously difficult organ for genetic medicines to access. Judo’s STRIKE (Selectively Targeting RNA Into KidnEy) platform uses a proprietary approach to create ligand-RNA conjugate drugs designed for receptor-mediated update by specific kidney cell types, resulting in gene silencing of disease-modifying target genes.
The company’s initial pipeline programs are “megalin-STRIKERs” that use the megalin receptor family to selectively deliver small interfering RNA therapeutics to the proximal tubule of the kidney to silence mRNA expression of specific solute carrier proteins (SLCs), thereby inhibiting the uptake of circulating solutes linked to systemic diseases. Targeting SLCs is an established approach for the treatment of various systemic diseases.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.